50 Years Ago in Corr: The Present Trend in Treatment of Osteogenic Sarcoma Albert B. Ferguson, Sr. CORR;14:63–69

Excerpt

This month’s symposium is devoted to papers presented at the 2008 Musculoskeletal Tumor Society Meeting in Phoenix, AZ, November 6–8, 2008. These papers reflect progress in the treatment of dreaded malignancies of the musculoskeletal system. Many malignant tumors of the musculoskeletal system are resistant to radiation therapy, and most had high death rates before the advent of chemotherapy in the 50s and 60s. As alternative chemotherapy agents were introduced, along with a better understanding of how they are used, sometimes in combination, the survival rates from most of these tumors markedly increased through the 70s and 80s, although some evidence suggests little further progress has been made in recent years [4]. Apart from multiple myeloma, osteogenic sarcoma is the most common of these primary bone tumors and sadly these most occur in patients between 10 and 20 years of age. …